In Phase C, participants will acquire ABBV-744 and oral navitoclax. In Segment D, members will receive ABBV-744 and ruxolitinib. Individuals will receive treatment till ailment progression or even the participants are not able to tolerate the study drugs. 88 These preclinical studies give paradigms for potential clinical trials in AML, https://abbv-744cancertreatmentcl02354.goabroadblog.com/31234045/not-known-details-about-brd4-inhibition-by-abbv-744-in-cancer-research-studies